#Canada #Vancouver #biotechnology #BioVaxys #Debenture Offering

BioVaxys Technology Corp. Completes Debenture Offering

BioVaxys Technology Corp. (CSE: BIOV) has announced a significant milestone in its financial journey with the successful closure of its unsecured convertible debenture offering. This strategic move signifies the company’s robust funding capabilities aimed at driving its innovative projects forward.

On September 16, 2025, BioVaxys reported that it raised a total of $335,670 through its non-brokered private placement of convertible debentures, an achievement that showcases confidence from investors in the company’s vision and product pipeline.

Details of the Offering

The convertible debentures, which are unsecured obligations of the company, carry an interest rate of 10% per annum and will mature on August 30, 2026. Interest on these debentures will be payable quarterly and can be settled either in cash or by converting into common shares, offering flexibility to investors in managing their returns. Notably, the principal amount of the debentures can be converted into shares at the holder's discretion, based on the closing price on the Canadian Securities Exchange on the day the notice of conversion is submitted.

Participants in the offering received additional benefits, specifically 4,000 transferable common share purchase warrants for each $1,000 in debentures. These warrants permit holders to acquire shares at an attractive exercise price of $0.25 per share until September 15, 2026. This incentivization is designed to enhance participation and shareholder engagement, further establishing a strong investor base for BioVaxys.

Utilization of Funds

The company disclosed that the proceeds from the offering will be allocated towards critical areas such as research and development, operational costs, and general corporate purposes. Notably, this strategic financial arrangement did not incur any finder’s fees, showcasing efficient capital-raising tactics without additional costs.

Furthermore, insiders demonstrated their confidence in the offering, with key executives James Passin and Kenneth Kovan both investing $25,000 each in debentures. Such participation underscores a positive outlook from BioVaxys leadership, enhancing trust among potential and existing investors.

Looking Forward

BioVaxys Technology Corp. is recognized for its commitment to developing pioneering biopharmaceutical solutions aimed at enhancing patient outcomes. The company is currently advancing several promising projects within its pipeline, including targeted therapies designed using its proprietary DPX™ immune-educating technology.

The biopharmaceutical sector is fraught with challenges, but with the added capital, BioVaxys is well-positioned to continue its ambitious development plans. The potential impact of their innovations in treating various medical conditions, including cancer and infectious diseases, remains significant.

Conclusion

As BioVaxys Technology Corp. continues to push the boundaries of biopharmaceutical development, this secured funding is a vital step towards realizing its long-term goals. Investors and stakeholders are keenly watching how the company leverages this financial boost to drive forward its mission of enhancing healthcare solutions. For more information, visit BioVaxys’s official website.